usdaed

I’ve been doing some research (read: spiralling down internet rabbit holes) and it seems these two are quite different. VOO is the sensible one, the one your mother would approve of. Solid, dependable, tracks the S&P 500. IWO, on the other hand, is…the artist. A bit more volatile, a bit more…ambitious. It focuses on smaller companies, which feels a bit like backing a promising but slightly flaky start-up. Units of Cryptocurrency Lost: 12. Hours Spent Watching Charts: 9. Number of Panicked Texts to Friends: 24.

Five years have passed since its inception, a mere blink in the grand scheme of financial epochs. It holds, as of late reckoning, some $1.9 billion in assets. A respectable sum, certainly, though easily lost amongst the towering piles of capital elsewhere. But to dwell on size alone is to miss the point entirely. It is not the weight of the coin, but the peculiar glint it possesses that truly captures the eye.

The aforementioned Shay Capital, it appears, has diminished its holdings in Sable Offshore. A reduction of 641,728 shares, valued at approximately $6.06 million based on the rather melancholy pricing of the fourth quarter of 2025. Their remaining stake, a mere 50,000 shares, suggests a distinct lack of enthusiasm, wouldn’t you agree? One suspects they’ve seen enough.

The cause of this little upward tick? Well, it appears the current unpleasantness has stirred up the oil prices, naturally. One wouldn’t expect calm seas when the geopolitical pot is bubbling, would one? But here’s the rather clever bit: ConocoPhillips, unlike some of its more globally-scattered brethren, is largely focused on these United States, Canada, and Alaska. A dashedly sensible arrangement, one might say.

Floor & Decor, you see, purveys the very foundations of domestic comfort – tiles, wood, the baubles and gewgaws with which we adorn our dwellings. A respectable enough trade, though hardly one to stir the passions. Yet, this company, despite a revenue of $4.68 billion and a net income of $207.65 million, finds itself trading at a mere $67.51 a share, a decline of 30.1% over the past year. A most unseemly tumble for a purveyor of permanence, wouldn’t you agree?

The major indices commenced the day looking distinctly unwell. The S&P 500 (^GSPC +0.24%) dipped a respectable 1.2%. The Dow Jones Industrial Average (^DJI +0.04%) followed suit, losing 1.1%. But the Nasdaq Composite (^IXIC +0.47%), ah, the Nasdaq! It truly embraces volatility, plunging a full 1.5% before remembering it had a reputation to uphold.

Monday saw a rally, inching towards the $150 mark. Last year it dared to peak at over $200, a fleeting moment of optimism. Is it a ‘no-brainer’ buy below that figure? One suspects the phrase is rather overused. Let’s just say it requires a degree of…optimism, shall we?

Some folks see this as a “buy the dip” opportunity. “It’s cheap!” they cry. And yes, it’s cheaper than a two-for-one sale on gefilte fish. It hasn’t been this low since 2008, which, let’s recall, wasn’t exactly a picnic. But before you start picturing yourself rolling in agricultural riches, let’s examine the fine print. You wouldn’t buy a used chariot without kicking the tires, would you?

The management, it appears, believes that preserving profit margins is paramount, even at the cost of attracting customers. The Chief Executive, Mr. Boatwright, has stated, in effect, that the price of a Chipotle meal is justified in its own right. This assertion, while perhaps sincere, is divorced from the simple fact that value is not inherent in an object, but is assigned by the purchaser. To insist on a price, regardless of the customer’s willingness to pay, is not a demonstration of confidence, but of a peculiar detachment from the market.

To suggest that Teva is “the best” healthcare stock to deploy a thousand dollars into is, admittedly, a rather pedestrian phrasing. Let us instead say it presents a peculiar opportunity. The fourth-quarter earnings report – a document often as thrilling as a beige wall – revealed a revenue of $4.7 billion, an 11% increase. Adjusted earnings per share clocked in at $0.96, a figure that, while exceeding analyst expectations (those charmingly optimistic soothsayers), was somewhat inflated by a $500 million windfall from Sanofi, relating to a drug candidate named duvakitug. A rather cumbersome name, don’t you think? It evokes images of a disgruntled duck. Stripped of this temporary gloss, growth settles into a more modest, yet still respectable, few percentage points. But beneath the surface, a metamorphosis is underway.